SCHEMBL2227757

SCHEMBL2227757

CC(C)C(C)Cc1ccc(O)c(O)c1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 9/20 0.92
ALOX12 P18054 7/20 0.92
KDM4E B2RXH2 3/20 0.92
RECQL P46063 3/20 0.92
HIF1A Q16665 3/20 0.92
HSD17B10 Q99714 3/20 0.92
MEN1 O00255 2/20 0.92
ALDH1A1 P00352 2/20 0.92
ESR1 P03372 2/20 0.92
TP53 P04637 2/20 0.92
CYP3A4 P08684 2/20 0.92
HPGD P15428 2/20 0.92
MAPK1 P28482 2/20 0.92
KMT2A Q03164 2/20 0.92
NR3C1 P04150 2/20 0.92
FOS P01100 2/20 0.92
TTR P02766 2/20 0.92
JUN P05412 2/20 0.92
HSD17B1 P14061 2/20 0.92
HSD17B2 P37059 2/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Masoprocol SCHEMBL3818 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL29434238 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL29434237 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL135976 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL29350884 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL13906133 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL29355090 0.96 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL28156467 0.94 ALOX15 (0.96) ALOX15ALOX12KDM4ERECQLHIF1A
SCHEMBL28992632 0.91 ALOX15 (0.76) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL2304515 0.90 ALOX15 (0.88) ALOX15ALOX12KDM4ERECQLHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103768754-A Fire-extinguishment composition containing unsaturated hydrocarbon compounds and derivatives thereof XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY 2014-05-07 CN claimed
CN-117428187-A Method for preparing carbon-coated copper by in-situ reduction of polydopamine-like copper oxide, carbon-coated copper and application 深圳大学 2024-01-23 CN disclosed
CN-103768754-B Fire extinguishing composition containing unsaturated hydrocarbon compound and derivatives thereof 湖北及安盾消防科技有限公司 2020-10-13 CN disclosed
US-20170233386-A1 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-08-17 US disclosed
US-20160083355-A1 COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION COMMISSARIAT ENERGIE ATOMIQUE (FR) 2016-03-24 US disclosed
CN-103768754-A Fire-extinguishment composition containing unsaturated hydrocarbon compounds and derivatives thereof XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY 2014-05-07 CN disclosed
US-20120283249-A1 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2012-11-08 US disclosed
US-20110166192-A1 PROCESS FOR CHARGING A POLYMERIC PRODUCT WITH ATTRIBUTE IMPARTING AGENT(S) ADITYA BIRLA SCIENCE & TECHNOLOGY CO. LTD. (IN) 2011-07-07 US disclosed
EP-1549301-A2 A METHOD FOR USING TETHERED BIS(POLYHYDROXYPHENYLS) AND O-ALKYL DERIVATIVES THEREOF IN TREATING INFLAMMATORY CONDITIONS OF THE CENTRAL NERVOUS SYSTEM Oklahoma Medical Research Foundation (US) 2005-07-06 EP disclosed
WO-2003103583-A2 A METHOD FOR USING TETHERED BIS(POLYHYDROXYPHENYLS) AND O-ALKYL DERIVATIVES THEREOF IN TREATING INFLAMMATORY CONDITIONS OF THE CENTRAL NERVOUS SYSTEM OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2003-12-18 WO disclosed
EP-0265514-B1 MEDICAMENTS FOR INHIBITING SKIN WRINKLING BLOCK DRUG COMPANY (US) 1993-03-31 EP disclosed
EP-0288534-B1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1991-12-18 EP disclosed
US-5008294-A Topical administration CHEMEX PHARMACEUTICALS, INC. (US) 1991-04-16 US disclosed
EP-0265514-A4 Medicaments for inhibiting skin wrinkling. CALIFORNIA HEALTH TECHNOLOGIES (US) 1990-01-11 EP disclosed
US-4880637-A ALCOHOLS, ETHERS OR ESTERS, AS ANTITUMOR AGENTS, SKIN DISORDERS CHEMEX PHARMACEUTICALS, INC. (US) 1989-11-14 US disclosed
WO-1988003806-A1 PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO disclosed
EP-0265514-A1 Medicaments for inhibiting skin wrinkling. CALIFORNIA HEALTH TECHNOLOGIES (US) 1988-05-04 EP disclosed
WO-1988001509-A1 PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1988-03-10 WO disclosed
WO-1987006829-A1 METHOD FOR INHIBITING AGING CALIFORNIA HEALTH TECHNOLOGIES (US) 1987-11-19 WO disclosed
US-3934034-A Hydroxy substituted diphenylalkyls for treatment of lipidemia SANDOZ, INC. (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283249-A1 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action HAVCR2, MAVS, ANTXR2 ALOX15 4418/4885ALOX12 4559/4885KDM4E 1528/4885
US-20160083355-A1 COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION HAVCR2, MAVS, ANTXR2 ALOX15 4522/4885ALOX12 4636/4885KDM4E 1212/4885
US-20170233386-A1 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action HAVCR2, MAVS, ANTXR2 ALOX15 4522/4885ALOX12 4636/4885KDM4E 1212/4885
US-20110166192-A1 PROCESS FOR CHARGING A POLYMERIC PRODUCT WITH ATTRIBUTE IMPARTING AGENT(S) IMPA1, PARG, AGPS ALOX15 2170/4885ALOX12 2144/4885KDM4E 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.